FDA Watch: Scientists Ask Agency to Rescind Approval for Opioid Management Test
Experts—including those in genetics and device regulation—say the AvertD assay did not predict risks of abuse ‘any better than chance’
Keep up to date on new and emerging diagnostic tests, testing trends and opportunities, and disruptive technologies
Experts—including those in genetics and device regulation—say the AvertD assay did not predict risks of abuse ‘any better than chance’